BNP PARIBAS ARBITRAGE/CALL/MODERNA/140/0.1/20.09.24 | Market Closed - Euronext Paris 12:30:01 2024-05-23 EDT | ||
| 3.455 EUR | +14.21% |
|
| Current month | +305.52% | ||
| 1 month | +382.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 3.455 | +14.21% |
| 24-05-22 | 3.025 | +63.96% |
| 24-05-21 | 1.845 | +1.10% |
| 24-05-20 | 1.825 | +23.73% |
| 24-05-17 | 1.475 | +1.37% |
Real-time Euronext Paris
Last update May 23, 2024 at 12:30 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| SG3NB | |
| ISIN | NLBNPFR1ZGR4 |
| Date issued | 2024-03-12 |
| Strike | 140 $ |
| Maturity | 2024-09-20 (120 Days) |
| Parity | 10 : 1 |
| Emission price | 0.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.465 € |
|---|---|
| Lowest since issue | 0.515 € |
| Spread | 0.01 € |
| Spread % | 0.29% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- SG3NB Warrant
